ISOSULFAN BLUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOSULFAN BLUE (ISOSULFAN BLUE).
Isosulfan blue is a dye that binds to serum proteins after intradermal injection, allowing visualization of lymphatic channels and lymph nodes during sentinel lymph node biopsy. It has no known pharmacological activity beyond its use as a visual contrast agent.
| Metabolism | Isosulfan blue is not metabolized; it is primarily excreted unchanged in bile and to a lesser extent in urine. Metabolites have not been characterized. |
| Excretion | Primarily excreted unchanged in bile via the hepatobiliary system (approximately 90%). Renal excretion accounts for less than 10% of the administered dose. |
| Half-life | Terminal elimination half-life is approximately 20-30 minutes. Clinically, the dye is rapidly cleared from the plasma, which correlates with its short duration of action as a lymphographic agent. |
| Protein binding | Approximately 80% bound, primarily to albumin. |
| Volume of Distribution | Approximately 0.2 L/kg, indicating distribution primarily within the extracellular fluid and limited tissue penetration. |
| Bioavailability | Not applicable as it is administered via subcutaneous or intradermal injection; bioavailability is 100% by these routes. |
| Onset of Action | Following subcutaneous or intradermal injection, visualization of lymphatic vessels occurs within 5-15 minutes. |
| Duration of Action | Lymphatic staining persists for 30-60 minutes after injection, sufficient for surgical identification of sentinel lymph nodes. |
1-2 mL (10-20 mg) of a 1% solution injected subcutaneously or intradermally around the tumor or into the tumor, typically 3-5 minutes prior to sentinel lymph node biopsy.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; however, caution is advised in severe renal impairment due to potential accumulation of excipients. |
| Liver impairment | No specific dose adjustment for hepatic impairment; use with caution in severe hepatic impairment as safety data are limited. |
| Pediatric use | 0.5-1 mL (5-10 mg) of a 1% solution injected subcutaneously or intradermally, adjusted based on body weight and clinical judgment. |
| Geriatric use | Same as adult dosing; monitor for hypersensitivity reactions and injection site reactions due to potentially increased skin fragility. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOSULFAN BLUE (ISOSULFAN BLUE).
| Breastfeeding | It is not known whether isosulfan blue is excreted in human milk. Because many drugs are excreted in breast milk, caution should be exercised when administered to a nursing woman. No M/P ratio available. Likely minimal systemic absorption; however, avoid breastfeeding for 24-48 hours after administration if possible. |
| Teratogenic Risk | Isosulfan blue is a diagnostic dye used for lymph node mapping. There are no adequate studies in pregnant women. Animal reproduction studies have not been conducted. It should be used during pregnancy only if clearly needed and if potential benefit justifies potential risk to fetus. No known teratogenic effects in first trimester; however, use is generally avoided unless necessary. Second and third trimester: No known fetal harm, but caution due to possible maternal hypersensitivity reactions causing fetal distress. Category C. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to isosulfan blue or any component of the formulation.","Known history of allergic reactions to triphenylmethane dyes."]
| Precautions | ["Hypersensitivity reactions: risk of anaphylaxis, including severe hypotension, angioedema, and bronchospasm. Monitor patients closely during and after administration.","Interference with pulse oximetry: transient decrease in oxygen saturation readings due to absorption of light at similar wavelengths.","Skin discoloration: blue-green discoloration of skin and urine, typically resolves within weeks.","Risk of injection site reactions: pain, edema, and ulceration at administration site."] |
Loading safety data…
| Fetal Monitoring | Monitor for hypersensitivity reactions (including anaphylaxis) during and after administration. Observe for changes in oxygen saturation, skin staining, and possible interference with pulse oximetry readings (may cause falsely low SpO2). Fetal monitoring may be considered if maternal reaction occurs. No specific fetal monitoring required for uncomplicated administration. |
| Fertility Effects | No known effects on fertility. No relevant animal or human data. |